Apellis Medical Hub
  • Science
    • PNH
    • Geographic Atrophy
    • C3G and Primary IC-MPGN
    • HSCT-TMA
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
    • Exploratory Data Analysis
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
    • Early Access & Compassionate Use Program
    • Prescribing Information
    • Community Letters
  • Search
  • This website is intended only for use by U.S. Healthcare Professionals.
  • Menu Menu
  • Science
    • PNH
    • Geographic Atrophy
    • C3G and Primary IC-MPGN
    • HSCT-TMA
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
    • Exploratory Data Analysis
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
    • Early Access & Compassionate Use Program
    • Prescribing Information
    • Community Letters
  • Search
  • This website is intended only for use by U.S. Healthcare Professionals.
Home / Congress Presentations / Geographic Atrophy / EURETINA 2023

Importance of automated OCT analysis for the longitudinal monitoring of geographic atrophy in clinical trials and the real-world

Share Via Email

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.

Report an Adverse Event or Product complaint

Please call 833-866-3346

Ask a Medical Question

Please click here or call
833-866-3346 (833-TO-MEDINFO)

Connect with an MSL

Set up a meeting with your
Medical Science Liaison

Privacy PolicyTerms and Conditions

©2025 Apellis Pharmaceuticals, Inc. All rights reserved. 04/25 MED-US-CORP-22-00001 v11.0
Scroll to top
You are now leaving ApellisMedicalHub.com

You are about to leave ApellisMedicalHub.com to visit a third-party website. We recommend reviewing the privacy policy and terms & conditions of any site you visit, as Apellis Pharmaceuticals, Inc. is not responsible for their content.

I agree
Landing

Landing

You are entering a website that is technical in nature and was created for scientific exchange with Healthcare Professionals. The content on this website may include scientific information about investigational compounds or indications that are not approved. Apellis does not support, endorse or recommend the unapproved use of any compound, including those discussed on this website.
Are you a Healthcare Professional licensed to practice in the country or region selected above? If you are not a Healthcare Professional, you will be redirected to www.apellis.com(Required)
Enter
Enter
Enter
Enter
Enter
Enter